CarlJuneMD

PubMed

• 387 citations
  Targeting cardiac fibrosis with engineered T cells.
  Haig Aghajanian, Toru Kimura, Joel G. Rurik, Aidan S. Hancock, Michael S. Leibowitz
  Nature. 2019-09-11
• 308 citations
  Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
  Julie C. Fitzgerald, Scott L. Weiss, Shannon L. Maude, David M. Barrett, Simon F. Lacey
  Critical Care Medicine. 2017-02-01
• 415 citations
  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
  Marco Ruella, David M. Barrett, Saad S. Kenderian, Olga Shestova, Ted J. Hofmann
  The Journal of Clinical Investigation. 2016-10-03

Journal Articles

• Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology  
  Carl June, MD, Frontiers in Neurology
• Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell  
  Vijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature
• Immunotherapy for Glioblastoma: Adoptive T-cell Strategies  
  Marcela V Maus, Carl H June, Clinical Cancer Research
• Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-Targeted T Cells  
  Shannon A Carty, Carl H June, David L Porter, Bruce L Levine, Rahul M Kohli, Nature
• CAR T Cell Immunotherapy for Human Cancer  
  Carl H June, Michael C Milone, Science Magazine
• Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia  
  Michael W Boyer, Bruce L Levine, Carl H June, Theodore W Laetsch, Clinical Cancer Research
• Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma  
  Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood
• Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer  
  Austin D Williams, Amy S Clark, Paul J Zhang, Julia Tchou, Bruce L Levine, Jennifer M Matro, Laurence J Cooper, Alycia So, Lynn M Schuchter, Carl H June, Angela M DeMi..., Clinical Cancer Research
• Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer  
  Nathan Singh, Marco Ruella, Carl H June, Current Hematologic Malignancy Reports
• Join now to see all

Abstracts/Posters

• A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia
  Carl H June, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  Carl H June, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
  Carl H June, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
  Carl H June, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Original Article Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
  Carl June, MD, ScienceDirect, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Integration of Immunotherapy Into Treatment for Hematologic Malignancies 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Integration of Immunotherapy Into Treatment for Hematologic Malignancies 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Genetically Modified Cell Therapy 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all